Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.41 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 5/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | PAK4 | O96013 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16522812 | 0.70 | NOS1 (0.42) | ROCK2ROCK1DYRK1ACDK2IDO1 | |
| SCHEMBL30852842 | 0.70 | NOS1 (0.42) | ROCK2ROCK1DYRK1ACDK2IDO1 | |
| SCHEMBL2630775 | 0.67 | IDO1 (0.44) | DYRK1APAK4IDO1TDO2PIM3 | |
| SCHEMBL10936657 | 0.65 | INSR (0.55) | PIM1PIM2CDC7KDM4ECYP2D6 | |
| SCHEMBL7572136 | 0.65 | JAK2 (0.55) | CLK4IDO1TDO2METAP2NOS1 | |
| SCHEMBL7572076 | 0.65 | ROCK2 (0.55) | ROCK2ROCK1PKN2PIM1DYRK1A | |
| SCHEMBL30869004 | 0.64 | TDO2 (0.36) | ROCK2ROCK1PKN2PIM1PIM2 | |
| SCHEMBL2630725 | 0.64 | METAP2 (0.41) | DYRK1AIDO1TDO2METAP2NOS1 | |
| SCHEMBL17389142 | 0.64 | CHEK1 (0.45) | ROCK2ROCK1PKN2PIM1CHEK1 | |
| SCHEMBL10838630 | 0.63 | ROCK2 (0.39) | ROCK2ROCK1PKN2PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9827244-B2 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-28 | — | — | US | disclosed |
| US-9827244-B2 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-28 | — | — | US | disclosed |
| US-20170000788-A1 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-01-05 | — | — | US | disclosed |
| US-20170000788-A1 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-01-05 | — | — | US | disclosed |
| US-9359351-B2 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-07 | — | — | US | disclosed |
| US-9359351-B2 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-07 | — | — | US | disclosed |
| WO-2016005330-A1 | DIHYDROPYRIDOPYRAZINE-1,8-DIONES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF VIRAL DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-01-14 | — | — | WO | disclosed |
| US-20160002227-A1 | CAP/ENDO DUAL INHIBITORS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | HOFFMANN LA ROCHE (CH) | 2016-01-07 | — | — | US | disclosed |
| US-20160002227-A1 | CAP/ENDO DUAL INHIBITORS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | HOFFMANN LA ROCHE (CH) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000788-A1 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | MME, CAPRIN1, XPNPEP1 | ROCK2 3011/4885ROCK1 2861/4885PKN2 4640/4885 |
| US-20160002227-A1 | CAP/ENDO DUAL INHIBITORS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | MME, CAPRIN1, XPNPEP1 | ROCK2 3011/4885ROCK1 2861/4885PKN2 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.